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valuation of the Safety and
ffectiveness of Renal Artery Stenting
fter Unsuccessful Balloon Angioplasty
he ASPIRE-2 Study
rishna Rocha-Singh, MD* Michael R. Jaff, DO,† Kenneth Rosenfield, MD,†
or the ASPIRE-2 Trial Investigators
pringfield, Illinois; and Boston, Massachusetts
OBJECTIVES This study sought to define the safety and durability of renal stenting after suboptimal/failed
renal artery angioplasty in patients with suspected renovascular hypertension.
BACKGROUND Few prospective multicenter studies have detailed the safety, efficacy, and long-term clinical
benefits of renal artery stent revascularization in hypertensive patients with aorto-ostial
atherosclerotic renal artery lesions.
METHODS This non-randomized study enrolled 208 patients with de novo or restenotic 70%
aorto-ostial renal artery stenoses, who underwent implantation of a balloon-expandable stent
after unsuccessful percutaneous transluminal renal angioplasty (PTRA), which was defined as
a 50% residual stenosis, persistent translesional pressure gradient, or a flow-limiting
dissection. The primary end point was the nine-month quantitative angiographic or duplex
ultrasonography restenosis rate adjudicated by core laboratory analysis. Secondary end points
included renal function, blood pressure, and cumulative incidence of major adverse events and
target lesion revascularization at 24 months.
RESULTS The stent procedure was immediately successful in 182 of 227 (80.2%) lesions treated. The
nine-month restenosis rate was 17.4%. Systolic/diastolic blood pressure decreased from 168
 25/82  13 mm Hg (mean  standard deviation) at baseline to 149  24/77  12 mm
Hg at 9 months (p  0.001 vs. baseline), and 149  25/77  12 mm Hg at 24 months (p
 0.001 vs. baseline). Mean serum creatinine concentration was unchanged from baseline
values at 9 and 24 months. The 24-month cumulative rate of major adverse events was 19.7%.
CONCLUSIONS In hypertensive patients with aorto-ostial atherosclerotic renal artery stenosis in whom PTRA
is unsuccessful, Palmaz (Cordis Corp., Warren, New Jersey) balloon-expandable stents
provide a safe and durable revascularization strategy, with a beneficial impact on
hypertension. (J Am Coll Cardiol 2005;46:776–83) © 2005 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.11.073Cardiology Foundation
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rtherosclerotic renal artery stenosis is a common disorder
ften associated with coronary artery disease (1), aorto-iliac
nd infra-inguinal arterial disease (2), impaired renal func-
ion (3), and hypertension (4). Despite the proven efficacy of
See page 784
urgical revascularization (5,6), endovascular therapy has
merged as the preferred strategy for treatment. Percutane-
us transluminal renal angioplasty (PTRA) and endolumi-
al stenting are being performed at an increasing rate
espite a paucity of well-controlled multicenter data with
ong-term clinical follow-up confirming their efficacy. Sev-
ral investigators who conducted single and multicenter
tudies and registries support the use of PTRA and stenting,
From the *Prairie Heart Institute, Springfield, Illinois; and †Massachusetts General
ospital, Boston, Massachusetts. This study was supported by a grant from Cordis
orporation, a Johnson & Johnson Company. Drs. Jaff, Rosenfield, and Rocha-Singh
re presently consultants for Cordis Corporation.p
Manuscript received November 25, 2003; revised manuscript received November 1,
004, accepted November 30, 2004.specially in patients with the most complex form of the
isease (7–10).
We report the results of the first multicenter study
erformed in patients who underwent the implantation of
alloon-expandable stents immediately after unsuccessful
TRA, followed up prospectively by independent core
ngiography and duplex ultrasound laboratories to monitor
he treatment safety, vessel patency, and long-term effects
n blood pressure and renal function.
ETHODS
his prospective longitudinal non-randomized study was
onducted at 23 U.S. medical centers between December
997 and May 1999. The ethical review committees of
articipating institutions approved the study, and all pa-
ients signed informed consent before enrollment. Patients
nrolled had uncontrolled hypertension, serum creatinine
oncentrations 3.0 mg/dl, 70% de novo or restenotic
enal artery atherosclerotic stenoses, and persistent peak-to-
eak translesional pressure gradient of 20 mm Hg, flow-
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September 6, 2005:776–83 Renal Artery Stentingimiting dissections, or residual 50% stenoses after PTRA
ttempts. Renal artery stenoses were unilateral or bilateral,
ithin 10 mm of the aorto-renal artery border. Patients with
ccessory (polar) renal arteries were eligible for inclusion in
he study if the arterial diameter was 4 mm. Pre-
rocedural hypertension, defined as a blood pressure
140/90 mm Hg, had been refractory to combined therapy
ith more than two antihypertensive agents administered in
ppropriate doses. Patients treated with a single antihyper-
ensive drug were also eligible if they had a 24 mm Hg
ncrease in systolic or a 10 mm Hg increase in diastolic
lood pressure within four months before enrollment.
Criteria for exclusion from the study included a successful
enal angioplasty, sequential stenoses in a single renal artery,
renal artery diameter 4 mm or 8 mm, an occluded
enal artery, the need for more than two stents, a major
ascular complication after PTRA, stenosis of a transplant
r bypass graft anastomosis, non-atherosclerotic disease,
erum creatinine 3.0 mg/dl, kidney length 8.0 cm,
ntolerance to aspirin, a life expectancy of fewer than two
ears, known hemorrhagic diathesis or hypercoagulable
tate, contraindication to receiving heparin, myocardial
nfarction within 30 days, an abdominal aortic aneurysm
easuring 4.0 cm in diameter, current pregnancy, inabil-
ty to grant informed consent, or patient refusal to undergo
urgery to repair the renal artery or vascular access site in the
vent of a complication.
Pre-procedural laboratory testing consisted of routine
creening blood and urine examinations, including a de-
ailed lipid profile, abdominal and renal ultrasound studies,
nd a nonselective aorto-renal angiogram. Brachial blood
ressure was measured in the sitting position according to
merican Heart Association guidelines (11).
evascularization procedure and follow-up. Aspirin, 81
o 500 mg, was administered at least one day before
ndergoing PTRA, and continued thereafter at the discre-
ion of the investigator in a daily dose of 81 to 500 mg.
ntra-arterial heparin, 3,000 to 10,000 U bolus, was admin-
stered during PTRA. The procedure was performed in a
tandard fashion via the transfemoral or brachial approach,
ith angiographic images obtained to best visualize the
rigin of the renal artery. When the operator determined
hat PTRA had failed based on the criteria described, the
atient was eligible for enrollment in the study and implan-
ation of the stent.
A Palmaz (Cordis Corp., Warren, New Jersey) balloon-
xpandable stent (P104, P154, P204) was inserted at min-
Abbreviations and Acronyms
MAE  major adverse events
MLD  minimum lumen diameters
OPC  objective performance criteria
PTRA  percutaneous transluminal renal angioplasty
QCA  quantitative computer angiographymum balloon inflation pressures of 6 to 13 atm. The final miameter of the stent was determined by the diameter of the
ully inflated delivery balloon. Proper positioning of the
tent was verified in multiple fluoroscopic views, and was
onsidered optimal when located within the renal artery
stium, entirely covering the lesion, and extending by 2
m into the aorta. The procedural end points consisted of
he smallest achievable residual stenosis and pressure gradi-
nt, obtained as simultaneous measurements. Final mea-
urements included minimal lumen diameter, percent resid-
al stenosis of the stented region, and mean translesion
ressure gradient after device implantation. The Brigham
nd Women’s Hospital Cardiovascular Research Institute
ngiographic Core Laboratory, Boston, Massachusetts,
nalyzed all angiographic images.
Patient follow-up included visits at 30 days and at 6, 9,
nd 24 months. At each visit, in addition to the collection of
lood and urine for routine laboratory screening, special
ttention was paid to adverse event surveillance and mea-
urements of resting systolic and diastolic blood pressure, as
escribed earlier, and the concurrent antihypertensive drug
egimen.
In the first 65 patients, nine-month renal angiography
as performed to evaluate for in-stent restenosis. In the
emainder of the population, restenosis was ascertained by a
ine-month renal artery duplex ultrasound examination,
ecause investigators thought that subjecting potentially
symptomatic patients to an invasive procedure was not
ustified. Renal artery duplex ultrasonography has been
hown to be highly accurate in predicting native renal artery
tenosis with a confirmed 91% sensitivity and a 97%
pecificity (12). Duplex ultrasonography of the renal artery
nd stent, recorded in real time, was performed according to
standardized protocol from the Washington Hospital
enter Vascular Ultrasound Core Laboratory. The duplex
ltrasound study was interpreted by the core laboratory as
ndicative of restenosis when the renal/aortic ratio within
he stent was 3.5, or when the absolute peak systolic
elocity within the stent was 200 cm/s with post-stenotic
urbulence. A confirmatory angiogram was performed if the
uplex ultrasound results suggested restenosis. Unscheduled
enal angiograms were performed in case of interim loss of
lood pressure control, deteriorating renal function without
ther systemic etiology, or other clinical manifestations
ointing to the development of significant renal artery
estenosis. The assigned core laboratories reviewed all an-
iographic, hemodynamic, and duplex studies obtained
uring long-term follow-up.
tudy end points. The primary end point of A Study to
valuate the safety and effectiveness of the Palmaz balloon
xpandable stent In the REnal artery after failed angioplasty
ASPIRE-2) was the incidence of in-stent renal artery
estenosis at nine months determined by duplex ultrasound,
s defined earlier, or by angiography, defined as 50%
iameter stenosis. Secondary end points included: 1) acute
rocedural success, defined as 30% residual stenosis im-
ediately after stent deployment as determined by the Core
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Renal Artery Stenting September 6, 2005:776–83aboratory and 5 mm Hg residual mean translesion
radient; 2) technical success, defined as the successful
lacement of the stent at the lesion site; 3) worsening of
enal function at 30 days, 6 months, 9 months, and 24
onths, defined by a 50% increase in serum creatinine if
he baseline level was 2.0 mg/dl, or a 1 mg/dl increase if
he baseline level was 2.0 mg/dl; 4) treatment benefit,
stimated from changes in systemic blood pressure and/or
oncurrent antihypertensive regimen at any time point of
he follow-up; 5) absence of major adverse events (MAE) at
0 days, 3 months, 6 months, 9 months, and 24 months,
efined as in-hospital procedure- or device-related death or
-wave myocardial infarction, target lesion revasculariza-
ion or significant systemic athero-embolic events resulting
n end-organ damage (e.g., unanticipated kidney/bowel
nfarct, lower extremity ulceration or gangrene, loss of renal
unction).
tatistical analysis. The ASPIRE-2 study was designed as
non-randomized, non-inferiority study. As such, renal
rtery stenting after failed/suboptimal PTRA was compared
ith routine PTRA by establishing an objective perfor-
ance criteria (OPC). This reflects the end point rate (i.e.,
enal artery restenosis), established by a literature review, as
he standard for comparison with a new technique or
echnology (i.e., renal artery stenting). A 200-patient sam-
le size was calculated using a 40% post-PTRA OPC
estenosis rate to compare with renal stent restenosis with
0% power, a 10% loss to follow-up rate, and an estimated
31% nine-month restenosis rate associated with the
almaz renal stent delivery system.
Results are presented as means  standard deviation.
ata were analyzed at 9 and 24 months on an intention-
o-treat basis, including all patients in whom treatment with
he balloon-expandable stent was attempted and 95% con-
dence intervals were calculated. All procedural complica-
ions and MAE are reported descriptively. The cumulative
ate of MAE is presented in a Kaplan-Meier survival
nalysis. Computations were performed with the SAS
tatistical analysis software package (SAS Institute Inc.,
ary, North Carolina).
ESULTS
he main baseline characteristics of the study population
re presented in Table 1. Approximately two-thirds of the
atients were women, with 68% current or previous smok-
rs, 53% treated for blood lipid abnormalities, and 26%
iabetic patients. Treatment of 252 lesions was attempted in
65 patients with single unilateral lesions and in 43 patients
ith bilateral lesions. One patient with bilateral disease
nderwent stenting of three separate lesions.
mmediate and nine-month angiographic and duplex
ltrasound results. The baseline characteristics of 244
esions with quantitative angiographic analyses available are
hown in Table 2. Renal artery stenoses were evenly
istributed between right and left renal arteries, in an ostial cosition in nearly 90%, and concentric in three-fourths of
ases. The mean percent diameter stenosis of the target
essel after PTRA was 35.5  20.1, versus –2.2  17.5
mmediately after stent implantation. The cumulative fre-
uency distribution of percent diameter stenosis by quanti-
ative angiographic analysis immediately before and after
tent implantation is shown in Figure 1. Acute procedural
uccess was observed in 182 of 227 lesions treated (80.2%).
At nine months, angiographic and/or duplex ultrasound
ollow-up examinations were available in 153 patients (74%)
nd 184 lesions treated (73%); 55 patients (26.4%) died,
ithdrew consent, refused follow-up testing, or were lost to
ollow-up. Of the 153 patients with nine-month testing, 89
atients (58%) underwent ultrasound only and 64 (42%) had
ither angiography and/or ultrasound. Restenosis was ob-
erved in 17.4% of lesions, well below the OPC-derived
estenosis rate of 40%. The number of patients who under-
ent “confirmatory” renal angiography after having an
bnormal duplex ultrasound was not explicitly tracked in
his trial. Among multiple clinical and angiographic char-
cteristics examined, a history of diabetes (p  0.03), a
maller pre-procedure reference vessel diameter (p  0.04),
nd smaller post-procedure in-lesion (p  0.04) and in-
tent (p  0.005) minimum lumen diameters (MLD) were
redictors of restenosis.
linical follow-up. The clinical status was ascertained in
94 (93%) and 164 (79%) patients at 9 and 24 months,
espectively. At two years, 85.9% of patients remained free
f target lesion revascularization.
Table 3 presents the impact of renal artery stenting on
ystolic and diastolic blood pressure measurements and the
umber of antihypertensive drugs prescribed before PTRA and
t follow-up. Compared with baseline measurements, signifi-
able 1. Baseline Demographic and Clinical Characteristics
f Patient Population (n  208)
Characteristic
ge, yrs (mean  SD; range) 69.6  9.9; 40–88
ender, male/female (% of patients) 37/63
moking history (% of patients)
Never 32
Current 21
Previous 47
erum creatinine, mg/dl (mean  SD, range) 1.4  0.5; 1–3
erum creatinine, 2 mg/dl (% of patients) 12.5
oronary artery disease (% of patients) 63
erebrovascular disease (% of patients) 39
iabetes mellitus (% of patients) 26
Type I 28
Type II 68
Undetermined 4
eripheral vascular disease (% of patients) 44
reated hyperlipidemia (% of patients) 53
umber of antihypertensive drugs (% of patients)
1 4
2 37
3 31
4 28ant decreases were observed in the mean systolic and diastolic
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September 6, 2005:776–83 Renal Artery Stentinglood pressures at all time points. The Kaplan-Meier cumu-
ative probability of treatment benefit is presented in Figure 2.
In the overall population, the mean serum creatinine
oncentration increased from 1.36  0.52 mg/dl at baseline
igure 1. Cumulative frequency distribution of percent diameter stenosis
y quantitative angiographic analysis immediately before and after stent
mplantation. (All lesions treated with QA data available.) **In-stent
easurements were used for post-procedure percent diameter stenosis. CI
Table 2. Baseline Quantitative Angiographic C
Characteristic
Bilateral stent implantation, n (%) of patients
Reference vessel diameter, mm (mean  SD; range)
Minimum lumen diameter, mm (mean  SD; range
Percent diameter stenosis (mean  SD; range)
Post-PTRA diameter stenosis, % (mean  SD; rang
Lesion length, mm
Target lesion vessel, % of 244 measurements
Right renal artery
Left renal artery
Target lesion location, % of 244 measurements
Proximal
Mid
Ostial
Distance from ostium, mm (mean  SD; range)
Eccentricity, % of 244 measurements
Concentric
Eccentric
Mean blood pressure, mm Hg (mean  SD; range)
Aortic
Renal
Translesion gradient, mm Hg (mean  SD; range)
PTRA  percutaneous transluminal renal angioplasty; SD confidence interval; COV  coefficient of variation; SD  standard
eviation.
p
to 1.40  0.61 mg/dl at 9 months (p  NS vs. baseline) to
.46  0.81 mg/dl at 24 months (p  0.04 vs. baseline). In
he subgroup of patients with baseline serum creatinine
oncentrations 1.5 mg/dl, the mean concentration was
.94  0.39 mg/dl at baseline, 1.87  0.58 mg/dl at 9
onths (p  NS), and 1.93  0.71 mg/dl at 24 months (p
NS). Of a total of 63 patients with a baseline serum
reatinine 1.5 mg/dl, 5 (7.9%) had worsening of renal
unction at nine months. At 24 months, the condition of 4
f 53 patients (7.5%) with abnormal baseline renal function
cteristics of 244 Lesions
43 (21)
4.8  1.1; 2.5–8.0
1.8  0.8; 0.0, 4.3
61.5  13.8 (7.4–100)
35.5  20.1; 9.1–84.6
6.5  3.2; 0.0–21.8
50.4
49.6
10.7
0.8
88.5
1.3  2.8; 0.0–14.56
74.2
25.8
167  35; 80–241
93  45; 14–190
73  46; 8–218
dard deviation.
able 3. Evolution of Blood Pressure and Antihypertensive
egimens During 24-Month Follow-Up
n Mean  SD p
ystolic blood pressure
Baseline 208 168  25
Discharge 202 148  22 0.001
1 month 196 152  24 0.001
6 months 182 149  23 0.001
9 months 178 149  24 0.001
24 months 158 149  25 0.001
iastolic blood pressure
Baseline 208 82  13
Discharge 202 71  12 0.001
1 month 196 75  11 0.001
6 months 182 77  11 0.001
9 months 178 77  12 0.001
24 months 158 77  12 0.001
umber of antihypertensive
medications
Baseline 208 2.8  0.9
1 month 208 2.4  1.1 0.001
6 months 197 2.5  1.2 0.001
9 months 196 2.4  1.2 0.001
24 months 182 2.3  1.3 0.001hara
)
e)values indicate the level of significance in paired t test-based comparisons of each
ime point with baseline.
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Renal Artery Stenting September 6, 2005:776–83ho were re-evaluated had worsened. However, in this
ohort with progressive renal dysfunction, no patients re-
uired temporary or permanent hemodialysis.
dverse clinical events. The cumulative rate of MAE after
4 months of follow-up was 19.7% (Table 4). The Kaplan-
eier analysis of the MAE-free survival is presented in Figure
. Other serious adverse clinical events, consisting of stent
hrombosis, major hemorrhage, and access site complications,
ccurred in 1%, 1.4%, and 4.8% of patients, respectively.
mong all clinical and angiographic variables examined, none
ere a significant predictor of MAE.
nilateral versus bilateral stenting. At nine months, an-
iographic or duplex ultrasound data were available for 65 of
he 87 lesions (75%) treated among the 43 patients with
ilateral renal artery stenoses, and for 119 lesions (72%)
mong the 165 patients with single unilateral stenoses. The
estenosis rate was 16.9% (11 of 65 lesions) in the subgroup
f patients with bilateral disease, versus 16.8% (20 of 119
esions) among patients with unilateral stenoses (p  NS).
separate analysis of the 43 patients who underwent
tenting for stenoses in both renal arteries showed the same
egree of treatment effect on systolic blood pressure and
ypertensive medications as in the overall cohort, although
igure 2. Probability of treatment benefit based on control of hypertension
E  standard error of the mean.he effect on diastolic pressure had mostly dissipated by the snd of follow-up. No significant difference was observed in
he overall probability of a treatment benefit among the 43
atients who underwent bilateral versus the 165 patients
ho underwent unilateral stenting. Furthermore, as ob-
erved in the group of patients with unilateral disease,
ilateral renal stenting had no measurable effect on long-
erm renal function (data not shown).
ISCUSSION
ur large, prospective multicenter evaluation shows that use
f stainless steel balloon-expandable stents for aorto-ostial
enal artery stenosis is a safe and effective therapy after
nsuccessful balloon angioplasty. Additionally, this study is
he first to define the pre-intervention and post-intervention
ngiographic characteristics and nine-month stent resteno-
is rate as determined by independent core angiographic and
uplex ultrasound laboratories. This study also establishes a
avorable impact of stent implantation on blood pressure
hroughout the 24-month follow-up.
Several single-center observational trials (7,13–14) have
stablished renal stenting as an attractive adjunct to con-
entional balloon angioplasty for atherosclerotic aorto-ostial
: Peto formula was used for SE calculation (25). CI confidence interval;tenosis because of its utility in resolving elastic recoil,
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September 6, 2005:776–83 Renal Artery Stentingissection flaps, and residual translesional pressure gradients
hat may occur after angioplasty. However, small patient
umbers, short follow-up durations, the potential for single-
enter bias, and the inconsistent use of core laboratories to
efine procedural success and stent patency limited these
tudies. Furthermore, early renal stent studies reported a
roubling incidence of major complications, including tech-
ical failure, stent thrombosis, renal and systemic athero-
mbolization, major hemorrhage, and death (15,16). Other
tudies also raised a concern over the incidence of late
n-stent restenosis, which ranged from 11% (7) to 44% (17).
ur multicenter evaluation of 208 patients quantified the
fficacy of renal stenting to resolve a post-PTRA residual
tenosis, reducing it from 35.5  20% post-PTRA to
2.2% after stenting (Fig. 1). Our experience also con-
rmed an excellent 94.9% technical success rate and high
rocedural safety as we noted no perforations, no renal
rtery ruptures, and no device or in-hospital procedure
elated deaths. Importantly, we observed a 1.4% rate of
linically evident in-hospital episodes of athero-
mbolization that were not associated with an increase in
ost-stent serum creatinine values or with mortality. By
omparison, surgical revascularization, although effective in
ontrolling hypertension and salvaging renal function, is
ssociated with a higher procedural risk of morbidity and
able 4. In-Hospital and Long-Term Major Adverse Events
mong 208 Patients
Event n (%)
n-hospital
Death 0
Q-wave myocardial infarction 0
Target lesion revascularization 0
Major embolic event 3 (1.4)
Stent thrombosis 1 (0.5)
Cerebrovascular event 0
Major hemorrhage 2 (1.0)
Other major vascular event 5 (2.4)
Temporary/permanent hemodialysis 0
ut-of-hospital up to 2 years
Death 1 (0.5)
Q-wave myocardial infarction 0
Target lesion revascularization 30 (14.4)
Major embolic event 10 (4.8)
Stent thrombosis 1 (0.5)
Cerebrovascular event 0
Major hemorrhage 1 (0.5)
Other major vascular event 6 (2.9)
Temporary/permanent hemodialysis 3 (1.4)/2 (0.9)
ombined (in- and out-of-hospital to 2 years)
Overall major adverse events 41 (19.7)
Death 1 (0.5)
Q-wave myocardial infarction 0
Target lesion revascularization 30 (14.4)
Major embolic event 13 (6.3)
Stent thrombosis 2 (1.0)
Cerebrovascular event 0
Major hemorrhage 3 (1.4)
Other major vascular event 10 (4.8)ortality (5,6,18,19). Our renal artery duplex-defined nine- month restenosis rate is comparable to the 11% rate re-
orted by Blum et al. (7) and is significantly better than the
4% rate noted by Tullis et al. (17). The significant
mprovement in MLD after successful stenting compared
ith balloon angioplasty is not merely cosmetic, because the
reater final MLD was associated with reduced restenosis
nd confirms the importance of a stent deployment strategy
o safely maximize the post-deployment MLD. Our study
orroborates this previous observation (14) and the known
ssociation between smaller pre-procedure reference vessel
iameter and increased nine-month restenosis rate.
Presently, there is no standardized method for the quan-
itative interpretation of renal angiograms. The presence of
n aorto-ostial stenosis often results in post-stenotic dilata-
ion, making the determination of a “normal” main renal
rtery reference diameter difficult, and may result in the
isual over-estimation of the severity of the renal artery
tenosis. In this study, inclusion criteria required a 70%
enal artery stenosis as assessed by visual estimation. How-
ver, our independent core angiographic laboratory defined
pre-intervention mean lesion severity of 61.5%. Similarly,
post-PTRA50% visually estimated residual stenosis was
equired for enrollment. However, the angiographic core
aboratory defined the mean residual stenosis as 35%. These
isual over-estimations of lesion severity by the angiogra-
her may ultimately impact the clinical decision to proceed
ith intervention for a physiologically insignificant stenosis
20) and may explain the variation in the hypertension
esponse noted in various studies. Although contrast an-
iography remains the gold standard for the determination
f renal artery lesion severity, our investigation suggests that
higher percent diameter threshold or use of quantitative
omputer angiography (QCA) should be adopted to con-
rm a critical renal artery stenosis in patients with suspected
enovascular hypertension.
linical efficacy. Stent implantation was associated with a
ignificant overall lowering of mean systolic and diastolic
lood pressure and a reduction of the number of anti-
ypertensive medications (Table 3). Blood pressure im-
rovement was observed within 24 h of successful stent
mplantation and persisted through 24 months of follow-up.
owever, despite a lowering of blood pressure in the cohort
n general, only 47% of all patients experienced a “cure” or
improvement” in blood pressure at 24 months. This lower
ate of clinical efficacy in our trial compared with other
eports may reflect differences in the definitions of cure and
mproved used in our study, the absence of a minimum
ystolic/diastolic blood pressure criterion, or the lack of
econdary confirmation of a critical renal artery stenosis by
ither duplex ultrasonography or QCA before study enroll-
ent. Other investigators have reported an improvement in
lood pressure in 62% (7) and 76% of patients (10) at
ne-year follow-up. Notably, both studies required duplex
ltrasonography or QCA documentation of a critical renal
tenosis before study enrollment. Therefore, it seems that
any of our patients may have had primary (essential)
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Renal Artery Stenting September 6, 2005:776–83ypertension, because they derived no demonstrable blood
ressure benefit from successful renal stenting. This incon-
istent blood pressure response to renal stenting highlights
he importance of appropriate patient selection, particularly
n light of the observed 19.7% major adverse event at
wo-year follow-up. Notably, we found no clinical, angio-
raphic, or procedure-related predictor of improved blood
ressure control. Although the mean impact on diastolic
lood pressure was more durable in the group with unilat-
ral disease, our patients, whether they were treated for
lobal ischemic nephropathy (bilateral stenosis or stenosis to
solitary functioning kidney) or for unilateral renal stenosis,
ad the same overall likelihood of improved blood pressure
ontrol.
An important concern surrounds the safety of stenting in
atients with atherosclerotic renovascular disease and renal
ysfunction. In 26 patients with baseline renal dysfunction
mean serum creatinine, 2.4  0.25 mg/dl) we observed no
ignificant decline in renal function at 24 months after stent
mplantation (serum creatinine, 2.3  0.8; p  NS).
urthermore, in patients with bilateral renal artery stenoses
nd renal dysfunction, stenting of both arteries at the same
igure 3. Survival free from major adverse events (MAEs), to 720 days. A
confidence interval; SE  standard error of the mean.etting was performed routinely without a deleterious effect fin renal function. This patient cohort with bilateral renal
therosclerosis and renal dysfunction is of particular clinical
nterest because natural history studies suggest that they
ay be at increased risk for renal atrophy and possible
rogression to end-stage renal disease (21,22). Unfortu-
ately, there are only limited reports of stent revasculariza-
ion to stabilize or slow progressive renal dysfunction in
atients with ischemic nephropathy (23–25). Although
hese studies suggest a potential role for renal stenting in
his highly selected population, they are limited by the small
umber of patients studied; limited clinical follow-up;
nconsistent definitions of renal function improvement,
tabilization, and decline; and lack of an optimally medically
reated control cohort. Our patient population with pre-
umed ischemic nephropathy was small (n  40), and
herefore, this pertinent question was not addressed in our
tudy.
tudy limitations. Several potential limitations of this
nvestigation must be considered in interpreting the results.
irst, our study was not a randomized comparison with a
edical therapy or balloon angioplasty control group, and
herefore direct comparisons are not possible. Second, as the
ients (n  201). Note: Peto formula was used for SE calculation (25). CIrst prospective trial of renal artery stenting to use a core
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September 6, 2005:776–83 Renal Artery Stentingaboratory to adjudicate adherence to angiographic inclusion
riteria and define angiographic success, we observed a
isparity between the visually assessed renal artery lesion
everity and the core laboratory measurements. This dispar-
ty may reflect the inherent inaccuracy of visual estimation,
perator inexperience, or technique. The inclusion of pa-
ients with non-critical renal lesions may, in part, explain
he relatively low percentage of patients who experienced a
avorable blood pressure response and emphasizes the po-
ential risk of exposing patients to an unnecessary invasive
herapy. Furthermore, it suggests the need to consider a
igher percent diameter stenosis threshold for intervention
hen visual estimation is used or the more consistent use of
n-line QCA. Finally, we encountered a relatively low
ercentage of patients (74%) who returned for the nine-
onth duplex Doppler or angiographic assessment for
n-stent restenosis. As such, we cannot exclude a potentially
igher restenosis rate in this cohort.
This prospective, multicenter investigation clearly estab-
ishes the safety and efficacy of aorto-ostial renal artery
tenting as an adjunct to balloon angioplasty stenosis, and
efines an acceptable nine-month restenosis rate of 17.4%
hile highlighting the challenges in identifying those pa-
ients who may maximally benefit from stent revasculariza-
ion. Although not a randomized trial, the low complication
ate and associated long-term clinical efficacy should estab-
ish stenting as the initial consideration in patients requiring
enal revascularization. Although near-term risks and mor-
ality are higher with surgery, the long-term clinical dura-
ility and stent patency must be defined by additional
tudies. In the near future, new technologies, including
rug-eluting renal stents and distal embolic protection
evices, may be routinely used to reduce restenosis and renal
thero-embolization to optimize clinical outcomes in se-
ected patient cohorts.
eprint requests and correspondence: Dr. Krishna Rocha-
ingh, Vascular Medicine Program, Prairie Heart Institute, PO
ox 19420, Springfield, Illinois 62794-9420. E-mail:
singh@prairieheart.com.
EFERENCES
1. Rihal CS, Textor SC, Breen JF, et al. Incidental renal artery stenosis
among a cohort of hypertensive patients undergoing coronary arteriog-
raphy. Mayo Clin Proc 2002;77:309–16.
2. Olin JW, Melia M, Young JR, et al. Prevalence of atherosclerotic renal
artery stenosis in patients with atherosclerosis elsewhere. Am J Med
1990;88:46N–51N.
3. Uza T, Takeji M, Yamada N, et al. Prevalence and outcome of renal
artery stenosis in atherosclerotic patients with renal dysfunction.
Hypertens Res 2002;25:537–42.
4. Pickering TG, Laragh JH. Renovascular hypertension. In: The Kid-
ney, Vol. 2. 4th edition. Brenner BM, Rector FC Jr., editors.
Philadelphia, PA: Saunders, 1991:1940–67. o5. Hansen KJ, Starr SM, Sands RE, et al. Contemporary surgical
management of renovascular disease. J Vasc Surg 1992;16:319–31.
6. Cambria RP, Brewster DC, L’Italien GJ, et al. The durability of
different reconstructive techniques for atherosclerotic renal artery
disease. J Vasc Surg 1994;20:76–87.
7. Blum U, Krumme B, Flugel P, et al. Treatment of ostial renal-artery
stenoses with vascular endoprostheses after unsuccessful balloon an-
gioplasty. N Engl J Med 1997;336:459–65.
8. Lederman RJ, Mendelsohn FO, Santos R, et al. Primary renal artery
stenting: characteristics and outcomes after 363 procedures. Am
Heart J 2001;142:314–23.
9. Dorros G, Jaff M, Mathiak L, et al., for the Multicenter Registry
Participants. Multicenter Palmaz stent renal artery stenosis revascu-
larization registry report: four-year follow-up of 1,058 successful
patients. Catheter Cardiovasc Interv 2002;55:182–8.
0. Zeller T, Frank U, Muller C, et al. Predictors of improved renal
function after percutaneous stent-supported angioplasty of severe
atherosclerotic ostial renal artery stenosis. Circulation 2003;108:
2244–9.
1. Perloff D, Grim C, Flack J, et al. Human blood pressure determination
by sphygmomanometery. Circulation 1993;88:2460–7.
2. Nchimi A, Biquet J, Brisbois D, et al. Duplex ultrasound as first-line
screening test for patients suspected of renal artery stenosis: prospec-
tive evaluation in high-risk group. Eur Radiol 2003;13:1413–9.
3. Dorros G, Prince C, Mathiak L. Stenting of a renal artery stenosis
achieves better relief of the obstructive lesion than balloon angioplasty.
Catheter Cardiovasc Diagn 1993;29:191–8.
4. White CJ, Ramee SR, Collins TJ, et al. Renal artery stent placement:
utility in lesions difficult to treat with balloon angioplasty. J Am Coll
Cardiol 1997;30:1445–50.
5. Rees CR, Palmaz JC, Becker GJ, et al. Palmaz stent in atherosclerotic
stenoses involving the ostia of the renal arteries: preliminary report of
a multicenter study. Radiology 1991;181:507–14.
6. Wilms GE, Peene PT, Baert AL, et al. Renal artery stent placement
with use of the Wallstent endoprosthesis. Radiology 1991;179:457–62.
7. Tullis MJ, Zierler RE, Glickerman DJ, Bergelin RO, Cantwell-Gab
K, Strandness DE Jr. Results of percutaneous transluminal angioplasty
for atherosclerotic renal artery stenosis: a follow-up study with duplex
ultrasonography. J Vasc Surg 1997;25:46–54.
8. Lamawansa MD, Bell R, House AK. Short-term and long-term
outcome following renovascular reconstruction. Cardiovasc Surg 1995;
3:50–5.
9. Cherr GS, Hansen KJ, Craven TE, et al. Surgical management of
atherosclerotic renovascular disease. J Vasc Surg 2002;35:236–45.
0. Beauman G, Vogel R. Accuracy of individual and panel visual
interpretations of coronary arteriograms: implications for clinical
decisions. J Am Coll Cardiol 1990;16:108–13.
1. Caps M, Zierler RE, Polissar N, et al. Risk of atrophy in kidneys with
atherosclerotic renal artery stenosis. Kidney Int 1998;53:735–42.
2. Waston PS, Hadjipetrou P, Cox SV, et al. Effect of renal artery
stenting on renal function and size in patients with atherosclerotic
renovascular disease. Circulation 2000;102:1671–7.
3. Harden PN, MacLeod MJ, Rodger RS, et al. Effect of renal-artery
stenting on progression of renovascular renal failure. Lancet 1997;349:
1133–6.
4. Beutler JJ, Van Ampting JM, Van De Ven PJ, et al. Long-term effects
of arterial stenting on kidney function for patients with ostial athero-
sclerotic renal artery stenosis and renal insufficiency. J Am Soc Nephrol
2001;12:1475–81.
5. Rocha-Singh K, Ahuja R, Sung CH, et al. Long-term renal function
preservation after renal artery stenting in patients with progressive
ischemic nephropathy. Catheter Cardiovasc Interv 2002;47:135–41.
PPENDIX
or a list of the investigators and institutions that partici-
ated in the ASPIRE-2 study, please see the online version
f this article.
